Mergers & Acquisitions - Shire

Filter

Current filters:

Shire

Popular Filters

1 to 25 of 26 results

GlobalData believes Shire-NPS deal to be 'robust'

GlobalData believes Shire-NPS deal to be 'robust'

15-01-2015

Ireland-headquartered drugmaker Shire’s deal to acquire NPS Pharmaceuticals is ‘robust’, according…

GattexGlobalDataMergers & AcquisitionsNatparaNPS PharmaceuticalsPharmaceuticalRare diseasesResearchShire

2014 a memorable year for M&A activity in pharma sector

2014 a memorable year for M&A activity in pharma sector

15-01-2015

2014 was a busy year for merger and acquisition activity in the pharmaceutical industry, but will be…

GlobalMergers & AcquisitionsPfizerPharmaceuticalShire

Shire to spend $5.2 billion to buy NPS Pharma

Shire to spend $5.2 billion to buy NPS Pharma

12-01-2015

Recently jilted Ireland-headquartered Shire says it is to acquire NPS Pharmaceuticals, confirming recent…

BiotechnologyEuropeGattexMergers & AcquisitionsNatparaNPS PharmaceuticalsRare diseasesRevestiveShire

Shire to receive $1.635 billion break fee from AbbVie

Shire to receive $1.635 billion break fee from AbbVie

21-10-2014

The board of Ireland-headquartered drugmaker Shire has said there is now no realistic prospect of AbbVie…

AbbVieBusiness FinanceCity Code on Takeovers and MergersFinancialMergers & AcquisitionsMergers and acquisitionsPharmaceuticalShireUSA

AbbVie board withdraws bid to acquire Shire

AbbVie board withdraws bid to acquire Shire

16-10-2014

Following takeover target Shire’s waiver of the three-day notice period, AbbVie said this morning that…

AbbVieIrelandMergers & AcquisitionsPharmaceuticalShireUSA

AbbVie reconsidering $54.6 billion acquisition of Shire

AbbVie reconsidering $54.6 billion acquisition of Shire

15-10-2014

US drugmaker AbbVie has told Ireland-headquartered Shire of its board of directors' intention to meet…

AbbVieFinancialIrelandMergers & AcquisitionsPharmaceuticalShire

Shire finally accepts AbbVie’s takeover offer

Shire finally accepts AbbVie’s takeover offer

18-07-2014

After a protracted and at times hostile courtship, Ireland-headquartered drugmaker Shire has finally…

AbbVieHumiraMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

Shire succumbs to AbbVie’s yet again increased offer of £53.20 per share

Shire succumbs to AbbVie’s yet again increased offer of £53.20 per share

14-07-2014

Ireland-headquartered Shire, which just on Friday confirmed it had finally entered talks with suitor…

AbbVieAdalimumabFinancialIrelandMergers & AcquisitionsPharmaceuticalShireUSA

Shire confirms it has entered into talks with AbbVie

Shire confirms it has entered into talks with AbbVie

12-07-2014

Following reports by the Bloomberg news service, on Friday Ireland-based drugmaker Shire confirmed that…

AbbVieIrelandMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

AbbVie comes up with higher offer for Shire of $51.5 billion

AbbVie comes up with higher offer for Shire of $51.5 billion

08-07-2014

As has been widely expected following the meetings last week with major shareholders of Ireland headquartered…

AbbVieMergers & AcquisitionsPharmaceuticalShire

Analysts view Shire defense as independent pharma

Analysts view Shire defense as independent pharma

24-06-2014

There has been quite a lot of reaction to yesterday’s presentation by Ireland-headquartered Shire's…

AbbVieMergers & AcquisitionsPharmaceuticalShire

Shire sets out robust defense for rejecting AbbVie takeover bid

Shire sets out robust defense for rejecting AbbVie takeover bid

23-06-2014

Ireland-headquartered Shire today presented a robust defense of its position as an independent pharmaceutical…

AbbVieMergers & AcquisitionsPharmaceuticalShire

Shire rejects unsolicited $46.5 billion takeover offer from AbbVie

Shire rejects unsolicited $46.5 billion takeover offer from AbbVie

20-06-2014

Ireland headquartered Shire has this morning revealed that it has received, and rejected, an unsolicited…

AbbVieMergers & AcquisitionsPharmaceuticalShire

Shire acquires Lumena Pharma, adding to rare disease portfolio

Shire acquires Lumena Pharma, adding to rare disease portfolio

12-05-2014

Ireland-headquartered drugmaker Shire says it will acquire San Diego, USA-based rare disease focussed…

Lumena PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesShire

Report: Life science companies experience IPO slowdown

10-12-2013

Life sciences companies have been completing fewer initial public offerings (IPOs) this season as the…

Mergers & AcquisitionsPharmaceuticalRocheSalix PharmaceuticalsShireUSA

Shire’s acquisition of ViroPharma will add $831m in revenue by 2018, says GlobalData

Shire’s acquisition of ViroPharma will add $831m in revenue by 2018, says GlobalData

19-11-2013

Ireland-based drugmaker Shire’s (LSE: SHP) buy-out of US orphan drug company ViroPharma (Nasdaq: VPHM)…

CinryzeEuropeFinancialMergers & AcquisitionsPharmaceuticalShireUSAViroPharma

Shire strengthens position in rare diseases with $4.2 billion buy of ViroPharma

Shire strengthens position in rare diseases with $4.2 billion buy of ViroPharma

11-11-2013

Ireland-based drugmaker Shire saw its share rise 2.2% to £33.16 shortly after markets opened this morning,…

CinryzeFirazyrMergers & AcquisitionsPharmaceuticalRare diseasesShireViroPharma

Shire to buy SARcode Bioscience for $160 million plus milestones

26-03-2013

In a third takeover announcement this year, Ireland-headquartered Shire (LSE: SHP) says it plans to acquire…

LifitegrastMergers & AcquisitionsOphthalmicsPharmaceuticalSARcode BiosciencesShire

Shire acquires Premacure to expand in new therapy area

13-03-2013

In a second acquisition so far this year, Ireland-headquartered drugmaker Shire (LSE: SHP) said on Tuesday…

BiotechnologyMergers & AcquisitionsOphthalmicsPharmaceuticalPremacureRare diseasesShire

Shire to acquire Lotus Tissue Repair for undisclosed price

09-01-2013

Ireland-headquartered drugmaker Shire (LSE: SHP) said yesterday that it has signed an agreement to acquire…

BiotechnologyLotus Tissue RepairMergers & AcquisitionsPharmaceuticalRare diseasesShire

Shire inks deal to buy Pervasis, adding Ph II drug candidate

13-04-2012

Ireland-headquartered biopharma firm Shire (LSE: SHP) said yesterday that it has signed an agreement…

Mergers & AcquisitionsPervasis TherapeuticsPharmaceuticalShire

1 to 25 of 26 results

COMPANY SPOTLIGHT

Menarini

Back to top